Avid Bioservices Crescita futura

Future criteri di controllo 1/6

Si prevede che Avid Bioservices aumenterà gli utili e i ricavi rispettivamente del 139% e 20% all'anno, mentre si prevede che l'EPS crescerà del 139.1% all'anno.

Informazioni chiave

139.0%

Tasso di crescita degli utili

139.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	28.4%
Tasso di crescita dei ricavi	20.0%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	07 Nov 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Aug 26

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Jul 29

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Mar 07

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Feb 28

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Dec 28

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Nov 10

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Oct 15

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

Jun 23

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Jun 12

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

May 21

Avid Bioservices GAAP EPS of $0.02 beats by $0.01, revenue of $36.7M beats by $3.26M

Sep 06

Laughing Water Capital - Avid Bioservices: Not A Binary Bet But A Real Business

Jul 27

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:CDMO - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
4/30/2027	237	9	21	N/A	2
4/30/2026	198	-4	8	18	5
4/30/2025	140	-19	-5	-2	5
7/31/2024	142	-144	-11	8	N/A
4/30/2024	140	-141	-21	11	N/A
1/31/2024	137	-18	-38	13	N/A
10/31/2023	141	-12	-56	2	N/A
7/31/2023	150	-3	-93	-8	N/A
4/30/2023	149	0	-91	-13	N/A
1/31/2023	141	116	-92	-15	N/A
10/31/2022	134	119	-89	-3	N/A
7/31/2022	126	123	-48	11	N/A
4/30/2022	120	128	-47	9	N/A
1/31/2022	116	10	-9	27	N/A
10/31/2021	106	9	8	27	N/A
7/31/2021	101	6	13	27	N/A
4/30/2021	96	3	21	31	N/A
1/31/2021	81	0	10	16	N/A
10/31/2020	73	-5	5	11	N/A
7/31/2020	70	-7	2	6	N/A
4/30/2020	60	-15	2	6	N/A
1/31/2020	64	-10	5	8	N/A
10/31/2019	64	-9	4	6	N/A
7/31/2019	56	-11	-8	-7	N/A
4/30/2019	54	-10	-13	-12	N/A
1/31/2019	43	-16	-18	-15	N/A
10/31/2018	37	-24	-23	-21	N/A
7/31/2018	39	-30	-25	-21	N/A
4/30/2018	54	-25	N/A	-26	N/A
1/31/2018	65	-17	N/A	-40	N/A
10/31/2017	69	6	N/A	-42	N/A
7/31/2017	79	11	N/A	-34	N/A
4/30/2017	58	-3	N/A	-39	N/A
1/31/2017	59	-17	N/A	-33	N/A
10/31/2016	54	-48	N/A	-30	N/A
7/31/2016	41	-57	N/A	-40	N/A
4/30/2016	44	-1	N/A	-40	N/A
1/31/2016	35	-60	N/A	-36	N/A
10/31/2015	34	-56	N/A	-38	N/A
7/31/2015	31	-55	N/A	-41	N/A
4/30/2015	27	-54	N/A	-36	N/A
1/31/2015	24	-51	N/A	-40	N/A
10/31/2014	22	-47	N/A	-39	N/A
7/31/2014	23	-42	N/A	-33	N/A
4/30/2014	22	-36	N/A	-28	N/A
1/31/2014	20	-34	N/A	-26	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che CDMO rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che CDMO rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che CDMO rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di CDMO ( 20% all'anno) crescerà più rapidamente del mercato US ( 9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di CDMO ( 20% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di CDMO è previsto essere elevato tra 3 anni

Avid Bioservices Crescita futura

Future criteri di controllo 1/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus EPS estimates fall by 29%

Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

Price target increased by 14% to US$14.00

Consensus EPS estimates fall by 21%

Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

Recent updates

Punch and Associates Sends Letter to Board of Directors of Avid Bioservices, Inc

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

Funds managed by GHO Capital Partners LLP and Ampersand Management LLC entered into a definitive merger agreement to acquire Avid Bioservices, Inc. (NasdaqCM:CDMO) for approximately $850 million.

President exercised options and sold US$173k worth of stock

Consensus EPS estimates fall by 29%

Avid Bioservices, Inc. Reiterates Earnings Guidance for the Fiscal Year 2025

Price target increased by 14% to US$14.00

First quarter 2025 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. to Report Q1, 2025 Results on Sep 09, 2024

Avid Bioservices, Inc., Annual General Meeting, Oct 16, 2024

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Avid Bioservices, Inc. (NASDAQ:CDMO) Surges 43% Yet Its Low P/S Is No Reason For Excitement

Consensus EPS estimates fall by 21%

Full year 2024 earnings: EPS misses analyst expectations

Avid Bioservices Provides Earnings Guidance for Fiscal Year 2025

Avid Bioservices, Inc. to Report Fiscal Year 2024 Final Results on Jul 02, 2024

Insufficient new directors

Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q

Avid Bioservices, Inc. announced delayed 10-Q filing

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

Avid Bioservices, Inc. Maintains Revenue Guidance for Full Fiscal Year 2024

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 40% Share Price Rise

Avid Bioservices, Inc. announced that it expects to receive $160 million in funding

We Think Avid Bioservices (NASDAQ:CDMO) Has A Fair Chunk Of Debt

Insufficient new directors

There's No Escaping Avid Bioservices, Inc.'s (NASDAQ:CDMO) Muted Revenues Despite A 39% Share Price Rise

Director recently bought US$135k worth of stock

Consensus EPS estimates fall by 121%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q2, 2024 Results on Dec 07, 2023

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Avid Bioservices, Inc. (NASDAQ:CDMO)

Independent Chairman recently bought US$191k worth of stock

Consensus EPS estimates fall by 139%

Price target decreased by 7.2% to US$19.25

Avid Bioservices, Inc. Reiterates Revenue Guidance for Full Fiscal Year 2024

Avid Bioservices, Inc. to Report Q1, 2024 Results on Sep 07, 2023

Avid Bioservices, Inc., Annual General Meeting, Oct 23, 2023

President exercised options and sold US$254k worth of stock

Price target decreased by 11% to US$19.75

President exercised options and sold US$519k worth of stock

Consensus revenue estimates fall by 14%

Time To Worry? Analysts Are Downgrading Their Avid Bioservices, Inc. (NASDAQ:CDMO) Outlook

New minor risk - Profit margin trend

Full year 2023 earnings: EPS misses analyst expectations

Avid Bioservices, Inc. to Report Q4, 2023 Results on Jun 21, 2023

Is Avid Bioservices (NASDAQ:CDMO) Using Too Much Debt?

Little Excitement Around Avid Bioservices, Inc.'s (NASDAQ:CDMO) Earnings As Shares Take 26% Pounding

Investor sentiment deteriorates as stock falls 15%

Are Investors Undervaluing Avid Bioservices, Inc. (NASDAQ:CDMO) By 49%?

Insider notifies of intention to sell stock

Independent Director recently sold US$142k worth of stock

Director exercised options and sold US$69k worth of stock

Chief Financial Officer notifies of intention to sell stock

Third quarter 2023 earnings released

Does Avid Bioservices (NASDAQ:CDMO) Have A Healthy Balance Sheet?

Investor sentiment deteriorates as stock falls 18%

Consensus EPS estimates fall by 217%

Director exercised options and sold US$60k worth of stock

Director exercised options and sold US$57k worth of stock

Independent Director recently sold US$87k worth of stock

President exercised options and sold US$117k worth of stock

Consensus forecasts updated

Director exercised options and sold US$116k worth of stock

Avid Bioservices, Inc. Revises Revenue Guidance for the Full Fiscal Year 2023

Avid Bioservices, Inc. to Report Q2, 2023 Results on Dec 06, 2022

Here's Why Avid Bioservices (NASDAQ:CDMO) Has A Meaningful Debt Burden